摘要
目的:探讨雷公藤多苷用于紫癜性肾炎患儿的疗效及对相关指标的影响。方法:回顾性分析77例紫癜性肾炎患儿资料,按用药不同分为对照组(38例)和观察组(39例)。对照组患儿给予抗过敏、抗血小板、营养支持等常规治疗。观察组患儿在对照组治疗的基础上给予雷公藤多苷片1 mg/(kg·d),分3次餐后服用。两组均连续用药12周。观察两组患儿的临床疗效,治疗前后白细胞介素(IL)-10、趋化因子9(CXCL9)、转化生长因子(TGF)-β_1、基质金属蛋白酶-9(MMP-9)、免疫球蛋白A(IgA)、IgG、IgM水平,并对观察组患儿的IL-10、CXCL9、TGF-β_1水平与IgA水平的相关性进行分析,记录不良反应发生情况。结果:观察组患儿总有效率显著高于对照组,不良反应发生率显著低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组患儿IL-10、CXCL9、TGF-β_1、MMP-9、IgA、IgG、IgM水平比较,差异均无统计学意义(P>0.05)。治疗后,两组患儿IL-10水平均显著高于同组治疗前,且观察组高于对照组,CXCL9、TGF-β_1、IgA、IgG水平均显著低于同组治疗前,且观察组CXCL9、TGF-β_1、IgA低于对照组,差异均有统计学意义(P<0.05);两组患儿治疗前后MMP-9、IgM水平比较差异均无统计学意义(P>0.05)。IL-10水平与IgA水平呈负相关(r=-0.636,P<0.001),CXCL9水平与IgA水平呈正相关(r=0.434,P<0.001),TGF-β_1水平与IgA水平呈正相关(r=0.350,P<0.001)。结论:在常规治疗的基础上加用雷公藤多苷治疗儿童紫癜性肾炎的疗效显著,可改善炎症及免疫因子水平,且安全性较好。
OBJECTIVE： To explore the efficacy of tripterygium glycosides for children with purpuric nephritis and its effects on related indicators. METHODS： 77 children with purpuric nephritis were randomly divided into control group （38 cases） and observation group （38 cases） . Control group received anti-allergy, anti-platelet, nutritional support and other conventional treatment; observation group was additionally given Tripterygium glycosides tablet 1 mg/（kg/d） for 3 times, taking after a meal. All patients were treated for 12 weeks. Clinical efficacy, IL-10, chemokine 9 （CXCLg）, transforming growth factor-β1（TGF-β1）, metal matrix protease-9 （MMP-9）, IgA, IgG, IgM before and after treatment in 2 groups were observed, the correlation of IL-10, CXCLg, TGF-β1 and IgA in observation group was analyzed, and the incidence of adverse reactions was recorded. RESULTS： The total effective rate in observation group was significantly higher than control group, the incidence of adverse reactions was significantly lower than control group, with statistical significances （P〈0.05）. Before treatment, there were no significant differences in the IL-10, CXCLg, TGF-β1,MMP-9, IgA, IgG and IgM in 2 groups （P〉0.05）. After treatment, IL-10 in 2 groups was significantly higher than before, and observation group was higher than control group, CXCL9, TGF-β1, MMP-9, IgA and IgG were significantly lower than before, CXCLg, TGF-β1 and IgA in observation group were lower than control group, with statistical significanees （P〈0.05）, while there were no significant differences in IgG, MMP-9 and IgM before and after treatment in 2 groups （P〉0.05）. IL-10 was negatively correlated with IgA （r=- 0.636, P〈0.001）, CXCL-9 was positively correlated with IgA （r=0.434, P〈 0.001）, and TGF-β1 was positively correlated with IgA （r=0.350,P〈0.001）. CONCLUSIONS： Based on conventional treatment, tripterygium glycosides has significant efficacy for purpuric nephritis, can improve inflammation and immune factor levels, with good safety.
出处
《中国药房》
CAS
北大核心
2016年第36期5085-5087,共3页
China Pharmacy
关键词
雷公藤多苷
紫癜性肾炎
免疫因子
炎症因子
疗效
安全性
Tripterygium glycosides
Purpuric nephritis
Immunity factors
Inflammatory factors
Efficacy
Safety
